A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases

BACKGROUND: Several bone-seeking radionuclides have been developed for palliation of metastatic bone pain since 1956, however, so far radium-223 dichloride is the first and only Food and Drug Administration (FDA) approved targeted alpha therapy for metastatic castration-resistant prostate cancer (mC...

Descripción completa

Detalles Bibliográficos
Autores principales: Myint, Zin W., El Khouli, Riham, Lemieux, Bryan, Yan, Donglin, St. Clair, William H., Liu, Xiaoqi, Kunos, Charles A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013149/
https://www.ncbi.nlm.nih.gov/pubmed/35428207
http://dx.doi.org/10.1186/s12885-022-09496-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013149/
https://www.ncbi.nlm.nih.gov/pubmed/35428207
http://dx.doi.org/10.1186/s12885-022-09496-2

Ejemplares similares